To investigate the effect of low-dose celecoxib on postoperative recurrence of colorectal adenomas.

A total of 213 patients admitted to the Department of Gastroenterology of Bozhou People′s Hospital from January 1, 2020 to March 1, 2022 due to colon polyps underwent endoscopic polypectomy with postoperative pathological manifestations of adenomatous polyps were included, and were randomly divided into observation group (108 cases) and control group (105 cases). The observation group was given low-dose celecoxib 200 mg, once a day. The control group was given the same dose placebo. Both groups were followed up for half of 1 year and 1 year. The recurrence rates and the incidences of adverse reactions (gastrointestinal bleeding, gastroduodenal ulcer and death) of the two groups were analyzed.

Half a year later, the recurrence rate of adenoma in the observation group (2/108) was lower than that in the control group (8/105); One year later, the recurrence rate of adenoma in the observation group (9/108) was still lower than that in the control group (23/105), with statistically significant differences (P<0.05). The incidence of adverse reactions in the observation group (2/108) was slightly higher than that in the control group (0/105) after six months of follow-up, without a statistically significant difference (P>0.05). The incidence of adverse reactions in the observation group (8/108) was higher than that in the control group (2/105) after one year of follow-up, with a statistically significant difference (P<0.05).

Oral low-dose celecoxib can effectively prevent the occurrence of colorectal adenomas, but the incidence of adverse reactions will increase with prolonged oral administration.